粉样β沉积预测了在没有认知障碍的老年人中杂货购物表现
Lisa A Zukowski1, Sarah A Brinkerhoff2, Ilana Levin1
1Department of Physical Therapy, High Point University, High Point, NC, USA.
Journal of Alzheimer's disease : JAD
|May 31, 2024
概括
杂货购物表现可以帮助识别阿尔茨海默病 (AD) 风险. 老年人中较高的粉样蛋白β (Aβ) 沉积与效率较低的购物相关,这表明早期的认知变化.
科学领域:
- 神经科学是一个神经科学.
- 认知科学 认知科学
- 老年学是一门学科.
背景情况:
- 存在对阿尔茨海默病 (AD) 风险因素敏感的查工具的需求,包括粉样蛋白β (Aβ) 沉积.
- 细微的认知变化,通常错过了标准测试,可以通过复杂的日常任务揭示出来.
研究的目的:
- 评估杂货购物业绩是否区分高风险老年人 (OAer) 与低风险 (OAlr) 和年轻人 (YA).
- 调查粉样蛋白-β (Aβ) 沉积是否预测老年人 (OA) 的杂货购物表现.
主要方法:
- 21个OAer,33个OAlr和28个YA完成了四次杂货购物试验.
- 性能指标包括试用时间,物品准确性,以及在杂货纸条,货架单元,品牌和货架上的视觉固定.
- 线性混合效应模型分析了群体差异和Aβ沉积对表现的影响.
主要成果:
- 老年人 (OAer和OAlr) 在最糟糕的购物试验中,与最好的相比,在正确的货架单位和品牌上表现出更多的固定.
- 在OA中,更大的Aβ沉积与较少的时间固定在正确的项目和更多的杂货票据固定在最糟糕的表现中有关.
- 较高的Aβ沉积与效率较低的视觉搜索策略和潜在的工作记忆受损相关.
结论:
- 杂货购物表现可以揭示与阿尔茨海默病 (AD) 风险相关的微妙认知缺陷.
- 胺β (Aβ) 沉积与老年人复杂任务期间视觉搜索策略和工作记忆受损有关.
相关概念视频
Alzheimer's Disease: Overview
462
Alzheimer's Disease (AD) is a continually advancing neurodegenerative disorder, distinguished by escalating memory loss, cognitive dysfunction, and dementia. The disease unfolds in three stages: preclinical, mild cognitive impairment (MCI), and dementia. Its onset is insidious, and the progression gradual, with the cause not well explained by other disorders.
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
462
Cognitive Development During Adulthood
92
Cognitive development continues throughout adulthood, undergoing significant shifts across early, middle, and late stages. Individual transition occurs from adolescent idealism to pragmatic and adaptable thinking in early adulthood. During this period, individuals learn to integrate personal beliefs with the recognition that other perspectives are equally valid. Exposure to the complexities of modern society, diverse experiences, and higher education contribute to this adaptive thought process,...
92
Alzheimer's Disease: Treatment
179
Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...
179


